| INCA034176 | A Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participants With Recurrent or Refractory cGVHD | Phase 2 | Active not recruiting | 32 | Jan 6, 2027 |
| Povorcitinib | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | Phase 3 | Active not recruiting | 617 | Dec 26, 2026 |
| topical ruxolitinib 1.5% cream | Study of the Safety and Efficacy of Ruxolitinib Cream for Non-Sclerotic Chronic Cutaneous Graft-Versus-Host Disease | Phase 2 | Completed · results | 24 | Oct 12, 2026 |
| INCB099280 | A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive | Phase 2 | Terminated | 73 | Sep 30, 2026 |
| INCB099280 | A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma | Phase 2 | Terminated | 63 | Sep 28, 2026 |
| Tafasitamab | Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients | Phase 3 | Active not recruiting | 899 | Sep 1, 2026 |
| INCB177054 | A Study to Evaluate INCB177054 in Participants With Select Advanced or Metastatic Solid Tumors | Phase 2 | Terminated | 9 | Jul 29, 2026 |
| retifanlimab | Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy. | Phase 2 | Completed | 206 | May 29, 2026 |
| itacitinib | A Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib | Phase 2 | Terminated | 18 | May 11, 2026 |
| Ruxolitinib | A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia | Phase 2 | Completed | 171 | Mar 3, 2026 |
| Ruxolitinib 10 MG Oral Tablet | Ruxolitinib, Human Chorionic Gonadotropin (uhCG/EGF), and Dose De-escalated Corticosteroids | Phase 2 | Terminated | 10 | Feb 27, 2026 |
| Ponatinib 15 MG | Study to Evaluate the Reinduction and Second Stop of TKI With Ponatinib in CML in Molecular Response (ResToP) | Phase 2 | Completed | 34 | Dec 31, 2025 |
| 225Ac-SSO110 + SoC | Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 ) | Phase 2 | Terminated | 2 | Dec 31, 2025 |
| Itacitinib | An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer | Phase 2 | Completed | 59 | Dec 24, 2025 |
| Ruxolitinib | Ruxolitinib for Early Lung Dysfunction After Hematopoietic Stem Cell Transplant | Phase 2 | Terminated | 7 | Sep 17, 2025 |
| INCAGN02385 | Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies | Phase 2 | Completed · results | 61 | Aug 25, 2025 |
| Pemigatinib | A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma | Phase 3 | Terminated · results | 167 | Jul 7, 2025 |
| INCB099280 | A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors | Phase 2 | Terminated · results | 5 | Jun 6, 2025 |
| Ruxolitinib Cream | A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | Phase 3 | Completed · results | 241 | May 21, 2025 |
| INCB000928 | INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders | Phase 2 | Completed · results | 84 | Apr 1, 2025 |
| Retifanlimab | Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck | Phase 2 | Completed · results | 176 | Mar 14, 2025 |
| Ruxolitinib Cream | A Study to Assess the Safety and Efficacy of Ruxolitinib Cream in Participants With Genital Vitiligo | Phase 2 | Completed · results | 49 | Mar 6, 2025 |
| Povorcitinib | Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria | Phase 2 | Completed · results | 136 | Feb 28, 2025 |
| Liposome-encapsulated Daunorubicin-Cytarabine | Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms | Phase 2 | Terminated · results | 12 | Feb 27, 2025 |
| Povorcitinib | A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (HS) | Phase 3 | Completed · results | 619 | Jan 7, 2025 |
| Ruxolitinib Cream | A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN) | Phase 3 | Completed · results | 190 | Dec 30, 2024 |
| tafasitamab | A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL) | Phase 2 | Terminated · results | 54 | Oct 22, 2024 |
| Ruxolitinib | Prevention of Severe Acute Graft-versus-host Disease in Pediatric Patients Using a daGOAT Model | Phase 2 | Completed | 40 | Oct 7, 2024 |
| Ruxolitinib Cream | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN) | Phase 3 | Completed · results | 204 | Oct 7, 2024 |
| Ruxolitinib | Ruxolitinib for Premalignant Breast Disease | Phase 2 | Completed · results | 84 | Aug 29, 2024 |
| Ruxolitinib | Ruxolitinib Pre-, During- and Post-HSCT for Patients With Primary or Secondary Myelofibrosis. | Phase 2 | Completed · results | 44 | May 1, 2024 |
| carboplatin | Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2). | Phase 3 | Completed · results | 308 | Apr 15, 2024 |
| Ruxolitinib 1.5% Cream | Topical Ruxolitinib 1.5% for Hidradenitis Suppurativa Treatment | Phase 2 | Terminated · results | 6 | Feb 23, 2024 |
| Retifanlimab | Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer | Phase 3 | Completed · results | 583 | Dec 15, 2023 |
| Ruxolitinib | Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer | Phase 2 | Completed · results | 23 | Dec 31, 2022 |
| Busulfan | JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis | Phase 2 | Completed · results | 61 | Dec 28, 2022 |
| Pembrolizumab | Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302) | Phase 3 | Completed · results | 129 | Aug 22, 2018 |
| Pembrolizumab | Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304) | Phase 3 | Completed · results | 89 | Jul 19, 2018 |
| Epacadostat | A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma | Phase 2 | Terminated | 50 | Dec 27, 2016 |
| Itacitinib | Study of Itacitinib in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer | Phase 2 | Terminated | 9 | Feb 2016 |